On Friday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened lower -8.81% from the last session, before settling in for the closing price of $1.93. Price fluctuations for TSHA have ranged from $1.19 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 129.39% over the last five years. Company’s average yearly earnings per share was noted 61.44% at the time writing. With a float of $153.61 million, this company’s outstanding shares have now reached $204.94 million.
The firm has a total of 52 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.01%, operating margin of -880.73%, and the pretax margin is -229.67%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 25.05%, while institutional ownership is 69.39%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 61.44% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 5.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.03, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Analysing the last 5-days average volume posted by the [Taysha Gene Therapies Inc, TSHA], we can find that recorded value of 2.26 million was better than the volume posted last year of 2.18 million. As of the previous 9 days, the stock’s Stochastic %D was 52.61%. Additionally, its Average True Range was 0.19.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 26.89%, which indicates a significant increase from 25.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.65% in the past 14 days, which was lower than the 104.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0819, while its 200-day Moving Average is $2.3849. Now, the first resistance to watch is $1.8467. This is followed by the second major resistance level at $1.9333. The third major resistance level sits at $1.9967. If the price goes on to break the first support level at $1.6967, it is likely to go to the next support level at $1.6333. Should the price break the second support level, the third support level stands at $1.5467.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 204,943K shares outstanding in the company with a market cap of 360.70 million. Presently, the company’s annual sales total 15,450 K according to its annual income of -111,570 K. Last quarter, the company’s sales amounted to 1,790 K and its income totaled -25,520 K.
